Meloxicam has been found to be safe and effective treatment for children with active juvenile rheumatoid arthritis.
Meloxicam, a selective COX-2 inhibitor in adult rheumatic diseases, decreases the frequency of gastrointestinal (GI) side effects compared to nonselective COX inhibitors. GI side effects related to nonselective COX inhibitors also develop in up to 50 percent of children with juvenile rheumatoid arthritis (JRA).
Researchers investigated the safety, efficacy and pharmacokinetics of meloxicam in 36 children with JRA who needed a nonsteroidal anti-inflammatory drug in a 12-week Phase I/II study with an open extension of up to 52 weeks. The researchers were led by Ivan Foeldvari and colleagues from Am Allgemeinen Krankenhaus Eilbek, Hamburg and Hospital General de Mexico, Mexico City, as well as University Children’s Hospital, Hannover and Boehringer Ingelheim Pharma KG, Biberach, both also in Germany.
Study participants were given meloxicam suspension 0.25 mg/kg once a day, and researchers used the Pediatric Rheumatology International Trials Organisation (PRINTO) criteria to evaluate safety and carry out periodic efficacy measures. Eighteen of the children
underwent pharmacokinetic (PK) evaluation.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!